2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Blood Banking, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Women’s Health, Adverse Events, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

2900 Protease-activated receptor-2 contributes to vaso-occlusion, pain, and nephropathy in a mouse model of sickle cell disease

Fatima Trebak, Joanna Miklosz2, Karnsasin Seanoon, PhD3, Nirupama Ramadas, PhD, MSc, BSc4, Chunsheng R. Chen, PhD5, Julie Tourn6, Brandi N Reeves, MD7, Malgorzata Kasztan, PhD8, John D. Belcher I, PhD9, Erica Sparkenbaugh, PhD10, Rafal Pawlinski, PhD11
1 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
2 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
3 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
4 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
5 University of Minnesota, Minneapolis, Minnesota, United States
6 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
7 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
8 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
9 University of Minnesota, Minneapolis, Minnesota, United States
10 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States
11 University of North Carolina at Chapel Hill, CHAPEL HILL, North Carolina, United States

Protease-activated receptor 2 (PAR-2) is a widely expressed G protein-coupled receptor found on epithelial, endothelial, and immune cells. It is activated by extracellular serine proteases, including coagulation factors VIIa and Xa, trypsin, and mast cell tryptase. PAR-2 is well known for its roles in modulating inflammation and chronic pain.

Sickle cell disease (SCD) is inherited hemoglobinopathy marked by episodic red blood cell sickling leading to vaso-occlusive episodes (VOE) and intravascular hemolysis that result in vascular inflammation, chronic pain and progressive end-organ damage. We previously demonstrated that chronic vascular inflammation in SCD mice is partially mediated by PAR-2 expressed on non-hematopoietic cells. However, PAR-2 is also expressed on hematopoietic cells, including neutrophils and mast cells. Hence, we generated wild-type (WT) and global PAR-2-deficient (KO) Townes non-sickle (AA) and sickle (SS) mice to investigate the role of PAR-2 in VOE, chronic pain, and end-organ damage.

Vascular stasis (VS) was assessed by dorsal skinfold chamber (DSFC) microscopy and laser Doppler flowmetry after hemoglobin (Hb) infusion (2 µmol/kg, i.v.). Mechanical hyperalgesia was evaluated with von Frey filaments testing. Sickle cell nephropathy was assessed using 24-hour urine samples. Cardiac hypertrophy and function were assessed by echocardiography. In selected experiments, genetic findings were validated with the PAR-2 blocking antibody SAM-11 (2 mg/kg, i.v.).

PAR-2 deficiency had no effect on complete blood counts in either AA or SS mice. Four-month-old SS-WT mice had significantly reduced skin microvascular blood flow (MBF) 1 hour after Hb injection (baseline: 21.4±2.5; post-Hb: 14.6±2.9 mL/min, p<0.001, n=7). In contrast, Hb did not significantly reduce MBF in SS-KO mice (baseline: 23.0±1; post-Hb: 20.7±2.0 mL/min, n=5). Pretreatment with SAM-11 also prevented the Hb-induced reduction in MBF (baseline: 20.9±2.1; post-Hb: 18.2±2.4 mL/min, n=5) observed in IgG-treated SS-WT mice (baseline: 21.4±0.7; post-Hb: 13.5±1.0 mL/min, p<0.0001, n=5). To confirm these findings, SS-WT mice were implanted with a DSFC to visualize dermal microvessels. Mice received IgG or SAM-11 (2 mg/kg, s.c.) 15 min before Hb infusion (1.2 μmol/kg, iv). In IgG-treated mice, VS occurred in 27.3, 19.0, 16.6 and 14.2% of pre-selected vessels at 1, 2, 3 and 4 hours, respectively. SAM-11 significantly reduced VS to 8.2, 5.9, 3.6 and 2.3% at the corresponding time points (p<0.01 for 1, 2, and 4 hours’ time points).

In mechanical hyperalgesia assays, 7-month-old SS-WT mice exhibited a lower mechanical threshold than AA-WT controls (0.32±0.05 vs 1.15±0.1, p<0.01), which was partially restored in SS-KO mice (0.67±0.07, p<0.05 vs SS-WT). Similarly, paw withdrawal frequency was higher in SS-WT mice than in AA-WT controls (4.85±0.2 vs 2.06±0.06, p<0.01) and was reduced in SS-KO mice (2.82±0.5, p<0.05 vs SS-WT).

Sickle cell nephropathy and cardiomyopathy were evaluated in 10-12 months old mice (n=7-15). Compared to AA-WT controls, SS-WT mice exhibited impaired urinary concentrating ability, evidenced by increased urine output (0.69±0.11 vs 4.3±0.3 ml/24 hs, p<0.0001), reduced urine osmolality (3275±258 vs 1462±83 mOsm/kg H2O, p<0.0001), albuminuria (17.0±2.8 vs 183.4±25.1 ug/24 hs, p<0.0001), and proteinuria (3.8.8±0.5 vs 10.9±1.1 mg/24 hs, p<0.0001). PAR-2 deficiency significantly improved renal outcomes in SS mice as evidenced by reduced urine output (2.85±0.4 ml/24 hs vs SS-WT, p<0.005), albuminuria (94.8±19.9 ug/24 hs vs SS-WT, p<0.05), and proteinuria (6.8±0.6 mg/24 hs vs SS-WT, p<0.01) without improving urinary osmolality (1570±108 mOsm/kg H2O vs SS-WT). PAR-2 deficiency did not affect any parameters in AA mice.

Cardiac hypertrophy, indicated by an increased heart weight to body weight ratio, and pulmonary hypertension assessed by an increased right ventricle-to-left ventricle (LV) weight ratio, were observed in SS mice regardless of PAR-2 expression. Additionally, SS-WT mice exhibited significantly increased LV mass and LV internal diameter compared to AA-WT controls, whereas ejection fraction and fractional shortening were unchanged. PAR-2 deficiency had no effect on these parameters. Likewise, hypertrophy of the kidney, liver, lung and spleen observed in SS-WT mice was not altered by PAR-2 deficiency.

Together these findings identify PAR-2 as a mediator of both acute and chronic complications in the murine model of SCD.

Rafal Pawlinski, PhD: No relevant conflicts of interest to declare.